Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants

NCT00169455 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Rotavirus Gastroenteritis

Interventions

BIOLOGICAL: Live attenuated human rotavirus vaccine

Sponsor

GlaxoSmithKline